Silicon Laboratories
SLAB
221.95
-0.68
-0.30%
Silicon Laboratories
US · SLAB
#1727 by market cap
Listed 1970
221.95
-0.68
-0.30%
Live - 5344 symbols - heartbeat 448s ago
· 2026-10-08 07:39
Pre-market
221.95
0.00%
After-hours
221.95
0.00%
- Market cap
- 7.41B
- P/E (TTM)i
- -189.70
- P/Bi
- 6.76
- EPSi
- -1.98
- Div yieldi
- 0.00%
- 52W posi
- 99%
Reader sentiment
Are you bullish or bearish on SLAB?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 27.37, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +34.29% YoY
Margins
- Gross margin
- 58.23%
- Operating margin
- -8.99%
- Net margin
- -8.27%
Key ratios & quality
- Altman Z-Scorei
- 27.37
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 868.27M | 473.79M | 510.93M | 720.86M | 1.02B | 782.26M | 584.39M | 784.76M |
| Gross profit | 521.40M | 280.21M | 294.85M | 425.39M | 642.56M | 460.59M | 312.19M | 456.98M |
| Selling & admin expenses | 197.84M | 163.17M | 166.75M | 185.02M | 190.97M | 147.00M | 145.45M | 174.28M |
| Research & development | 238.35M | 205.69M | 235.19M | 273.21M | 332.33M | 337.74M | 332.23M | 353.25M |
| Operating profit | 85.21M | -88.64M | -107.09M | -32.84M | 119.26M | -24.15M | -165.49M | -70.54M |
| Pretax profit | 72.16M | -96.01M | -132.20M | -58.18M | 126.45M | -10.54M | -154.81M | -57.91M |
| Tax | -11.43M | 6.98M | -14.60M | 13.43M | 38.45M | 7.94M | 36.20M | 7.00M |
| Net profit | 83.59M | 19.27M | 12.53M | 2.12B | 91.40M | -34.52M | -191.01M | -64.91M |
| Basic EPS | 2 | 0 | 0 | 49 | 3 | -1 | -6 | -2 |
| Diluted EPS | 1.90 | 0.43 | 0.28 | 47.78 | 2.54 | -1.09 | -5.93 | -1.98 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Revenue | 177.71M | 192.85M | 206.00M | 208.21M | 213.50M | 228.19M |
| Gross profit | 97.78M | 108.11M | 119.02M | 132.08M | 127.00M | 140.67M |
| Selling & admin expenses | 41.64M | 43.16M | 43.68M | 45.81M | 55.49M | 56.32M |
| Research & development | 88.22M | 87.82M | 87.69M | 89.52M | 88.59M | 95.02M |
| Operating profit | -32.08M | -22.87M | -12.34M | -3.25M | -17.08M | -10.67M |
| Pretax profit | -28.57M | -19.29M | -9.52M | -534.00K | -13.69M | -8.43M |
| Tax | 1.90M | 2.53M | 414.00K | 2.15M | 2.21M | 2.16M |
| Net profit | -30.47M | -21.82M | -9.94M | -2.68M | -15.90M | -10.59M |
| Basic EPS | -1 | -1 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.94 | -0.67 | -0.30 | -0.08 | -0.48 | -0.32 |
Balance sheet
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 826.64M | 943.86M | 975.82M | 2.24B | 1.46B | 737.93M | 602.03M | 674.02M |
| Cash & ST investments | 613.82M | 725.97M | 724.68M | 2.04B | 1.19B | 439.22M | 382.16M | 443.62M |
| Inventory | 74.97M | 73.06M | 47.86M | 49.31M | 100.42M | 194.30M | 105.64M | 95.57M |
| Total assets | 1.62B | 1.67B | 1.99B | 2.96B | 2.17B | 1.44B | 1.22B | 1.27B |
| Total current liabilities | 144.85M | 137.70M | 284.50M | 668.83M | 185.78M | 163.57M | 97.88M | 143.79M |
| Short-term debt | -- | -- | 134.48M | 450.60M | -- | 45.00M | 5.88M | 6.93M |
| Long-term debt | 354.77M | 368.26M | 428.95M | -- | 529.57M | -- | -- | -- |
| Total liabilities | 557,064,000.00 | 559,802,000.00 | 793,646,000.00 | 745,871,000.00 | 764,420,000.00 | 234,374,000.00 | 142,653,000.00 | 174,899,000.00 |
| Total equity | 1.07B | 1.12B | 1.20B | 2.21B | 1.41B | 1.21B | 1.08B | 1.09B |
| Retained earnings | 961.34M | 980.61M | 993.66M | 2.21B | 1.42B | 1.19B | 1.00B | 936.81M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Total current assets | 618.67M | 617.75M | 652.56M | 674.02M | 676.32M | 671.22M |
| Cash & ST investments | 424.81M | 415.54M | 439.03M | 443.62M | 438.86M | 397.24M |
| Inventory | 83.40M | 80.87M | 82.19M | 95.57M | 103.23M | 123.34M |
| Total assets | 1.23B | 1.22B | 1.25B | 1.27B | 1.27B | 1.25B |
| Total current liabilities | 119.72M | 120.67M | 145.31M | 143.79M | 132.48M | 124.15M |
| Short-term debt | -- | -- | -- | 6.93M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 161,077,000.00 | 159,985,000.00 | 182,354,000.00 | 174,899,000.00 | 167,927,000.00 | 158,254,000.00 |
| Total equity | 1.07B | 1.06B | 1.07B | 1.09B | 1.10B | 1.09B |
| Retained earnings | 971.25M | 949.43M | 939.50M | 936.81M | 920.92M | 910.33M |
Cash flow
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 173.54M | 166.52M | 135.72M | -100.44M | 71.81M | -30.35M | -13.91M | 95.71M |
| Depreciation & amortization | 60.01M | 52.93M | 58.84M | 62.56M | 56.60M | 51.08M | 48.59M | 38.09M |
| Free cash flow | 149.08M | 151.22M | 117.63M | -129.02M | 45.28M | -52.63M | -25.66M | 65.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -25.97M | -12.22M | -1.27M | -1.14B | -871.65M | -202.53M | 16.33M | 14.64M |
| Ending cash balance | 197.04M | 227.15M | 202.72M | 1.07B | 499.92M | 227.50M | 281.61M | 364.22M |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| Operating cash flow | 48.13M | 4.91M | 34.32M | 8.35M | 4.93M | -14.51M |
| Depreciation & amortization | 11.69M | 9.80M | 8.36M | 8.24M | 8.34M | 8.42M |
| Free cash flow | 43.28M | -3.79M | 27.93M | -1.63M | -4.90M | -26.83M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 528.00K | 6.49M | -- | -- |
| Ending cash balance | 324.88M | 314.46M | 341.40M | 364.22M | 383.09M | 362.19M |
Returns & efficiency
| Line item | 2018 | 2019 | 2021 | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 8.28 | 1.77 | 1.08 | 124.11 | 5.05 | -2.64 | -16.69 | -5.97 |
| ROA %i | 5.29 | 1.17 | 0.68 | 85.52 | 3.57 | -1.91 | -14.33 | -5.21 |
| ROIC %i | 6.85 | 1.68 | 1.86 | 106.94 | 3.69 | -2.78 | -17.16 | -6.53 |
| 5-year avg ROE %i | 6.06 | 5.39 | 4.83 | 28.10 | 28.06 | 25.87 | 22.18 | 20.77 |
| EBIT margin %i | 10.58 | 8.34 | 5.58 | -3.77 | 13.00 | -0.64 | -26.27 | -7.26 |
| FCF / sales %i | 17.17 | 17.94 | 13.00 | -- | 4.42 | -- | -- | 8.38 |
| Current ratioi | 5.71 | 6.85 | 3.43 | 3.35 | 7.87 | 4.51 | 6.15 | 4.69 |
| Quick ratioi | 4.74 | 5.82 | 2.88 | 3.20 | 6.80 | 2.86 | 4.46 | 3.53 |
| Debt / assetsi | 21.84 | 21.99 | 28.26 | 15.23 | 25.24 | 4.49 | 1.75 | 1.89 |
| LT debt / equityi | 33.24 | 33.03 | 35.75 | -- | 38.97 | 1.64 | 1.44 | 1.56 |
| Interest coveragei | 4.66 | 3.45 | 1.45 | -0.87 | 19.81 | -0.90 | -117.18 | -58.40 |
| Revenue CAGR (3Y) %i | 10.43 | -12.10 | -12.74 | -6.01 | 29.30 | 15.26 | -6.76 | -8.49 |
| Net income CAGR (3Y) %i | 41.37 | -32.08 | -35.68 | 193.68 | 68.03 | -- | -- | -- |
| FCF CAGR (3Y) %i | 16.54 | 8.63 | -12.78 | -- | -33.10 | -- | -- | 13.26 |
| Line item | 2025-04 | 2025-07 | 2025-10 | 2026-01 | 2026-04 | 2026-07 |
|---|---|---|---|---|---|---|
| ROE %i | -14.77 | -9.71 | -8.00 | -5.97 | -4.65 | -3.63 |
| ROA %i | -12.82 | -8.47 | -6.88 | -5.21 | -4.03 | -3.16 |
| ROIC %i | -15.61 | -10.67 | -8.92 | -6.53 | -5.34 | -4.25 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -19.12 | -14.11 | -11.08 | -7.26 | -5.13 | -3.65 |
| FCF / sales %i | 13.95 | 10.68 | 9.91 | 8.38 | 2.15 | -- |
| Current ratioi | 5.17 | 5.12 | 4.49 | 4.69 | 5.11 | 5.41 |
| Quick ratioi | 3.98 | 3.91 | 3.48 | 3.53 | 3.89 | 3.84 |
| Debt / assetsi | -- | -- | -- | 1.89 | -- | -- |
| LT debt / equityi | -- | -- | -- | 1.56 | -- | -- |
| Interest coveragei | -115.56 | -92.44 | -80.57 | -58.40 | -45.62 | -33.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Industrial & Commercial is the largest reported line at 59.14% of revenue, across 2 reported segments.
- Home & Life follows at 40.86%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Industrial & Commercial59.14%
Home & Life40.86%
Quote time 2026-10-08 07:39:15 · For reference only, not investment advice and not tailored to your situation.